Pharmacosmos Acquires G1 Therapeutics in $405 Million Deal to Expand Cancer Drug Reach

G1 Therapeutics, the biotech firm behind the innovative lung cancer drug Cosela, has been acquired by Pharmacosmos in a $405 million deal. Cosela, approved by the FDA in 2021, is the first drug of its kind designed to protect bone marrow during chemotherapy for extensive-stage small cell lung cancer. Despite G1's success in the U.S. market, the company faced challenges in expanding the drug's application to other cancers and markets, leading to the decision to sell. Pharmacosmos, a company known for its expertise in iron deficiency anemia treatment, sees the acquisition as a strategic move to broaden its focus to oncology and enhance the global availability of Cosela.

The acquisition marks a significant shift for both companies. For Pharmacosmos, the deal represents an entry into the cancer care market, complementing its existing portfolio with a drug that has already shown commercial promise. G1 Therapeutics, initially spun out of the University of North Carolina, had been seeking partnerships to extend Cosela's reach, particularly in Europe and other regions. With this acquisition, Pharmacosmos plans to leverage its global infrastructure to bring Cosela to more patients worldwide, focusing on minimizing chemotherapy-induced myelosuppression in lung cancer patients.

This transaction, approved by the boards of both companies, is expected to close by the end of the third quarter of this year. G1 Therapeutics' CEO, Jack Bailey, expressed confidence that Pharmacosmos' expertise in supportive care will accelerate Cosela's global adoption, providing greater hope to cancer patients than G1 could achieve independently. The acquisition underscores the ongoing consolidation in the biotech sector as companies seek to expand their therapeutic offerings and global reach.

Click here to read the original news story.